Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A sharply higher dividend yield has investors focused on whether Pfizer can sustain large cash returns while facing revenue pressure from expiring patents.
THE APEX TIMES
THE APEX TIMES
A Yahoo Finance market recap pointed to several high-profile companies making “big moves” this week, including UnitedHealth (UNH), alongside HCA Healthcare, CrowdStrike, RXO and Enovis.
THE APEX TIMES
A market note argues that a change around Wegovy could re-shape parts of the GLP-1 landscape, yet Eli Lilly is not written out of the obesity-drug race.
THE APEX TIMES
The Eli Lilly partner Omada has jumped more than 118% over roughly three months, according to a new market roundup, as the company appears to be working through a fresh market “base.”
THE APEX TIMES
The retailer said it has launched its first new neighborhood-focused CVS Pharmacy in Houston, a format designed to broaden access to everyday pharmacy care. CVS also indicated it intends to bring a similar rollout to additional locations.
THE APEX TIMES
Joyner argued that insurers need stronger evidence that current GLP-1 list prices will produce enough “downstream” healthcare savings to justify covering broader use for weight loss.
THE APEX TIMES
The stock is trading in a so-called buy zone above a technical pivot near 1,133.95, as the market prepares for the company’s second-quarter results expected Aug. 5 and weighs a reportedly $3 billion deal.
THE APEX TIMES
The stock has climbed sharply over the past six months, reaching $62.97 per share, as investors reacted to what one market piece described as “solid” quarterly performance.
THE APEX TIMES
The Prozac maker is reported to have acquired a psychedelics-focused company in a transaction valued at $2.8 billion, betting that next-generation approaches could treat mental health conditions that today’s daily pills do not fully address.
